Skip to main content
HLB Pep Co., Ltd. logo

HLB Pep Co., Ltd. — Investor Relations & Filings

Ticker · 196300 ISIN · KR7196300008 KO Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2021-09-01 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 196300

About HLB Pep Co., Ltd.

http://hlbpep.co.kr/eng/main/

HLB Pep Co., Ltd. is a biopharmaceutical company specializing in the research, development, and production of peptide-based biomaterials and new drugs. The company's core activities include the manufacturing of peptide Active Pharmaceutical Ingredients (APIs) in a GMP-certified facility. It offers a range of products and services, including generic peptides, custom peptide synthesis for research and development, and a catalog of approximately 1,000 research peptides such as hormones and neuropeptides. HLB Pep focuses on discovering new drug candidates and aims to commercialize them through technology transfer.

Recent filings

Filing Released Lang Actions
[기재정정]전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system regarding the exercise of conversion rights (convertible bonds) by the company Anygen. It details the number of shares to be issued, the conversion price, and the updated listing date. This type of filing relates to changes in capital structure and share issuance resulting from the conversion of debt into equity, which falls under the 'Share Issue/Capital Change' category.
2021-09-01 Korean
전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding the exercise of conversion rights (전환청구권행사) for convertible bonds. This involves the issuance of new shares resulting from the conversion of debt into equity, which falls under capital changes. According to the provided definitions, announcements regarding new share issues or capital changes are classified as SHA.
2021-08-27 Korean
[기재정정]사업보고서 (2020.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Anygen Co., Ltd. for the fiscal year ending December 31, 2020. It contains detailed financial information, management discussions, business descriptions, and corporate governance details. It is a comprehensive annual filing required by the Korean financial authorities (Financial Supervisory Service/KRX). According to the provided definitions, this corresponds to the 10-K category. FY 2020
2021-08-17 Korean
반기보고서 (2021.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for Anygen Co., Ltd., covering the period from January 1, 2021, to June 30, 2021. It contains detailed financial data, business operations, and management information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2021
2021-08-17 Korean
[기재정정]단일판매ㆍ공급계약체결
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from a Korean company (Anygen) regarding a 'Correction Report' (정정신고) for a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결). It details changes to the contract amount and duration due to client clinical trial updates. Since this is a specific regulatory disclosure regarding a material business contract update that does not fit into the other specialized categories like M&A or Earnings, it falls under the 'Regulatory Filings' (RNS) category.
2021-06-01 Korean
분기보고서 (2021.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Anygen Co., Ltd.' covering the period from January 1, 2021, to March 31, 2021. It contains detailed financial information, business descriptions, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-05-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.